HUTCHMED (China) (H7T2) AI Stock Analysis

0 Followers

HUTCHMED (China)

(Frankfurt:H7T2)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Conservative Balance SheetDebt-to-equity of about 0.08 and a sizable equity base leave HUTCHMED with financial flexibility to continue R&D and absorb operating volatility. Conservative leverage can reduce balance-sheet stress while the company works to improve profitability and cash-flow consistency.

Negative Factors

Revenue ContractionThe negative growth rate and multi-year revenue volatility indicate that commercial momentum has not yet become consistent. Continued contraction can reduce resources available for research and commercialization, while making future earnings more dependent on successful product launches or pipeline progress.

HUTCHMED (China) (H7T2) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.95B
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 164.4
Beta (1Y): 0.21
Revenue Growth: -15.02%
EPS Growth: -96.45%
Country: Germany
Employees: 1,796
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

HUTCHMED (China) Business Overview & Revenue Model

Company Description

HUTCHMED (China) Limited, a biopharmaceutical company established in 2000 and headquartered in Central, Hong Kong, focuses on the discovery, development, and commercialization of innovative targeted therapies and immunotherapies. The company primaril...

HUTCHMED (China) Risk Analysis

HUTCHMED (China) disclosed 90 risk factors in its most recent earnings report. HUTCHMED (China) reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

HUTCHMED (China) Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:H7T2 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:3692	75Outperform	HKD 212.37B	27.22	18.26%	1.41%	24.97%	43.23%
HK:1513	74Outperform	HKD 29.06B	17.83	11.32%	6.32%	-9.56%	-23.22%
HK:0867	61Neutral	HKD 25.71B	14.26	8.60%	3.31%	14.80%	-2.88%
HK:2196	57Neutral	HKD 67.71B	17.23	7.14%	2.69%	9.88%	9.30%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:6185	51Neutral	HKD 13.79B	660.78	0.60%	―	36.09%	―

* Healthcare Sector Average

Performance Comparison

DE:H7T2 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:H7T2	HUTCHMED (China) Limited	2.56	0.04	1.59%
HK:0867	China Medical System Holdings	10.39	-3.38	-24.57%
HK:1513	Livzon Pharmaceutical Group Class H	24.62	-4.45	-15.32%
HK:2196	Shanghai Fosun Pharmaceutical (Group) Co Class H	16.73	-5.74	-25.54%
HK:3692	Hansoh Pharmaceutical Group Company Limited	34.36	-3.59	-9.46%
HK:6185	CanSino Biologics, Inc. Class H	26.70	-17.46	-39.54%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

HUTCHMED (China) AI Stock Analysis